Tesamorelin

Also known as: Egrifta, TH9507

Metabolic

Approved

Tesamorelin is the only FDA-approved GHRH analog, indicated for HIV-associated lipodystrophy (excess abdominal fat accumulation). It stimulates GH release from the pituitary in a physiologically natural pulsatile manner and has demonstrated significant visceral fat reduction in clinical trials.

Regulatory & Approval Status

FDA Approved

Tesamorelin is an FDA-approved peptide drug (marketed as Egrifta) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.